Diabetes

News

Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.

News

The FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.

News

Eli Lilly's ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.

News

Novo Nordisk has reported the first clinical data with its triple G agonist for diabetes, in China, as it starts an international trials programme.

News

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.

News

New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.